The U.S. plasmid DNA manufacturing market size surpassed USD 490 million in 2025 and is predicted to reach around USD 2564.58 million by 2035, registering a CAGR of 18% from 2026 to 2035. Strong investment in gene therapy and product commercialization is boosting the market.

U.S. Plasmid DNA Manufacturing Market Statical Scope

The U.S. plasmid DNA manufacturing market is significantly fueled by a robust and continuously evolving pipeline of gene therapies in development. Furthermore, the complex and individualized nature of genetic and cancer therapies necessitates highly specialized and scalable plasmid DNA manufacturing processes.

Biotech companies and research institutions are investing heavily in the development of flexible production platforms that adhere to rigorous quality standards and meet the volume demands of both clinical and commercial applications.

U.S. Plasmid DNA Manufacturing Market Share, By Grade, 2025 (%)

• GMP grade - Good Manufacturing Practice (GMP) grade plasmid DNA suitable for clinical applications. The GMP grade segment dominated with 55% share due to its vital role in large-scale therapeutic production and regulatory compliance.
• R&D grade - Plasmid DNA grade used for research and development purposes. This segment dominated with 45% share, driven by early-stage cell and gene therapy development.

U.S. Plasmid DNA Manufacturing Market Share, By Development Phase, 2025 (%)

• Clinical therapeutics - Plasmid DNA used in clinical trials for therapeutic applications. The clinical therapeutics segment dominated the market with 45% share, driven by growing demand for plasmids in ongoing clinical research and development.
• Marketed therapeutics - Plasmid DNA used in FDA-approved treatments. This segment held 30% share, due to clinical trials and commercial approvals for gene and cell therapies.

U.S. Plasmid DNA Manufacturing Market Share, By Application, 2025 (%)

• Cell & gene therapy - Plasmid DNA used in cell-based and gene therapy treatments. Cell & gene therapy segment dominated the market with 50% share due to the growing market for personalized treatments and regenerative medicine.
• DNA vaccines - Plasmid DNA used for the development of vaccines. The DNA vaccines segment held 30% share due to rising focus on novel therapy for disease prevention.

U.S. Plasmid DNA Manufacturing Market Share, By Disease, 2025 (%)

• Cancer - Plasmid DNA used in the development of cancer treatments, such as immunotherapies and gene therapies. The cancer segment dominated with 40% share due to the significant market demand for cancer treatment.
• Genetic disorder - Plasmid DNA used for gene therapies targeting genetic disorders. The genetic disorders segment held 30% share, driven by demand for advanced treatment to treat genetic problems.

Top Companies in the U.S. Plasmid DNA Manufacturing Market

• Charles River Laboratories
• VGXI, Inc.
• Danaher (Aldevron)
• Kaneka Corp.
• Cell and Gene Therapy Catapult
• Eurofins Genomics
• Lonza
• Luminous BioSciences, LLC
• Akron Biotech
• Catalent, Inc.

Segments Covered in the Report

By Grade

• GMP grade
• R&D grade

By Development Phase

• Clinical therapeutics
• Marketed therapeutics
• Pre-Clinical Therapeutics

By Application

• Cell & gene therapy
• DNA vaccines
• Immunotherapy
• Others

By Disease

• Cancer
• Genetic disorder
• Infectious Disease
• Others